Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Monika Raut, Gautamjeet Singh, Immaculata Hiscock, Sheetal Sharma & Nameeta Pilkhwal. (2022) A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma. Expert Review of Hematology 15:7, pages 607-617.
Read now
Read now
Changxia Shao, Jinan Liu, Wei Zhou, Monika K. Raut, Matthew Monberg, Xiting Cao, Alejandro D. Ricart & Arun Balakumaran. (2019) Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin. Leukemia & Lymphoma 60:4, pages 947-954.
Read now
Read now
Thomas E. Delea, Arati Sharma, Aaron Grossman, Caitlin Eichten, Keenan Fenton, Neil Josephson, Akshara Richhariya & Alison J. Moskowitz. (2019) Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma. Journal of Medical Economics 22:2, pages 117-130.
Read now
Read now
Machaon Bonafede, Joseph Feliciano, Qian Cai, Virginia Noxon, Nicole Princic, Akshara Richhariya & David J Straus. (2018) Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure. ClinicoEconomics and Outcomes Research 10, pages 629-641.
Read now
Read now
Articles from other publishers (6)
Christopher Yasenchak, Nicholas Liu, April Beeks, Michelle Fanale, Nicholas Robert, Ding He & Kristina S. Yu. (2023) Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice Perspective. JCO Oncology Practice.
Crossref
Crossref
Alnecia R Nisbett, Xiaoqin Yang, Patrick Squires, Santosh Gautam, Kaushal Desai, Monika Raut & Akash Nahar. (2022) Treatment patterns and clinical outcomes among patients with relapsed/refractory classical Hodgkin's lymphoma. Future Oncology 18:32, pages 3623-3636.
Crossref
Crossref
Gian Luca Breschi, Federica Demma, Paolo Morelli & Maria De Francesco. (2021) Brentuximab vedotin in adult patients with HL CD30+ at high risk of relapse or progression following ASCT: a cost-analysis in Italy. AboutOpen 8:1, pages 81-87.
Crossref
Crossref
François Laliberté, Monika Raut, Xiaoqin Yang, Guillaume Germain, Akash Nahar, Kaushal D. Desai, Sean D. MacKnight, Shuvayu S. Sen & Mei Sheng Duh. (2020) Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA. Targeted Oncology 16:1, pages 85-94.
Crossref
Crossref
Renhong Huang, Xiaowei Zhang, Sadia Sophia, Zhijun Min & Xiaojian Liu. (2018) Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma. Anti-Cancer Drugs 29:4, pages 364-370.
Crossref
Crossref
Shelagh M. Szabo, Ishan Hirji, Karissa M. Johnston, Ariadna Juarez-Garcia & Joseph M. Connors. (2017) Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study. PLOS ONE 12:10, pages e0180261.
Crossref
Crossref